Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (2)
  • Open Access


    Racial Disparities in Clinical Features and Survival Outcomes among Patients with Pancreatic Neuroendocrine Tumor: A Contemporary SEER Database Analysis

    Fei Wang1, Jihyun Ma2, Nan Zhao3, Chi Lin3,*, Haixing Jiang1,*

    Oncologie, Vol.24, No.4, pp. 865-895, 2022, DOI:10.32604/oncologie.2022.025447

    Abstract Objective: The characteristics of clinical features and prognoses among patients with different racial backgrounds have not been clearly studied. We thus investigated the clinical characteristics and overall survival (OS) differences among Asian, White, and Black patients with pancreatic neuroendocrine tumors (pNETs). Materials and Methods: The Surveillance, Epidemiology, and End Results (SEER) database was queried to identify patients with pNETs between 1983 and 2015. We performed univariable (UVA) and multivariable logistic regression (MVA) to assess the association between variables and race category. A Kaplan-Meier (KM) plot was used to calculate the OS rates. The Cox proportional hazard regression was used to… More >

  • Open Access


    Classifications des tumeurs neuroendocrines gastroentéropancréatiques : ce qui change*
    Classifications of gastro-entero-pancreatic neuroendocrine tumors: what has changed ?

    J.-Y. Scoazec

    Oncologie, Vol.21, No.2, pp. 119-124, 2019, DOI:10.3166/onco-2019-0052

    Abstract The WHO classification of the tumors of endocrine organs, published in July 2017 and that of digestive tumors, released in July 2019, have introduced significant changes in the classification of gastro-entero-pancreatic neuroendocrine tumors (NETs), which was unchanged since 2010. The main change is a new category of well-differentiated neoplasms, NET G3, in addition to the two previous categories NET G1 and NET G2. The other changes are: 1) the cut-off in Ki-67 index between NET G1 and G2, now set at 3%, 2) the term used for mixed tumors: MiNEN (mixed neuroendocrine-non neuroendocrine neoplasm) instead of MANEC (mixed adenoneuroendocrine carcinoma).… More >

Displaying 1-10 on page 1 of 2. Per Page